Hookipa Pharma (NASDAQ:HOOK - Get Free Report) issued its quarterly earnings data on Thursday. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.24, Zacks reports. Hookipa Pharma had a negative net margin of 405.28% and a negative return on equity of 72.30%. The company had revenue of $36.60 million for the quarter, compared to the consensus estimate of $3.20 million. During the same period last year, the firm posted ($0.27) EPS.
Hookipa Pharma Stock Performance
NASDAQ HOOK traded down $0.03 during mid-day trading on Friday, hitting $0.77. The stock had a trading volume of 623,570 shares, compared to its average volume of 1,319,507. The company has a 50 day simple moving average of $0.78 and a 200 day simple moving average of $0.68. Hookipa Pharma has a 52-week low of $0.41 and a 52-week high of $2.05.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on HOOK. Royal Bank of Canada reiterated an "outperform" rating and set a $5.00 price target on shares of Hookipa Pharma in a research note on Monday, March 25th. HC Wainwright dropped their price objective on Hookipa Pharma from $6.50 to $5.00 and set a "buy" rating on the stock in a report on Friday, April 26th.
View Our Latest Stock Report on HOOK
About Hookipa Pharma
(
Get Free Report)
HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.
See Also
Before you consider Hookipa Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hookipa Pharma wasn't on the list.
While Hookipa Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
